世界临床药物2024,Vol.45Issue(9) :972-979.DOI:10.13683/j.wph.2024.09.013

特应性皮炎病情严重程度和疗效评估量表研究进展

Progress of scales for assessing the severity and treatment efficacy in atopic dermatitis

高婷婷 王瑞平
世界临床药物2024,Vol.45Issue(9) :972-979.DOI:10.13683/j.wph.2024.09.013

特应性皮炎病情严重程度和疗效评估量表研究进展

Progress of scales for assessing the severity and treatment efficacy in atopic dermatitis

高婷婷 1王瑞平2
扫码查看

作者信息

  • 1. 武汉市第一医院皮肤科,湖北武汉 430022
  • 2. 上海市皮肤病医院,同济大学附属皮肤病医院临床研究与创新转化中心,上海 200443
  • 折叠

摘要

近年来,特应性皮炎(atopic dermatitis,AD)的发病率逐渐上升,尤其是儿童群体,且其中重症者占比明显升高.AD患者临床瘙痒症状明显,且易反复发作,对患者及其家庭的生活质量造成严重影响.临床上,在AD诊治过程中,准确掌握病情严重程度的变化情况有助于及时调整用药和治疗方案.因此,对AD患者的皮损严重程度进行规范评估和长期管理至关重要.当前,临床上共存在60多种AD皮损严重程度的评估工具,包括基于医生评估和患者主观感受的评估.该文根据国内外最新版的专家共识,对常用评估工具的使用方法和优缺点进行系统梳理,以便临床医务工作者更好地选择、使用这些评估工具.

Abstract

In recent years,the incidence rate of atopic dermatitis(AD)has gradually increased,especially the incidence rate of AD and the proportion of severe patients in children.AD patients have obvious clinical itching symptoms,and are prone to recurrent episodes,which seriously affects the quality of life of patients and their families.In clinical practice,accurately understanding the changes in the severity of AD patients during the diagnosis and treatment is helpful to timely adjust clinical medication and treatment plans.Therefore,it is crucial to conduct standardized assessment and long-term management of the severity of skin lesions in AD patients.Currently,there are over 60 assessment tools for the severity of AD skin lesions in clinical practice,including those based on physician evaluations and patient subjective perceptions.This article systematically sorted out the usage methods,advantages and disadvantages of commonly used assessment tools based on the latest version of the national and international expert consensus,in order to facilitate clinical staff to better choose and use these assessment tools.

关键词

特应性皮炎/皮损严重程度/评估工具/量表/专家共识

Key words

atopic dermatitis/the severity of skin lesion/evaluation tool/scale/expert consensus

引用本文复制引用

基金项目

上海市人才发展基金(2021SHRCFZ01)

上海申康医院发展中心第二轮三年行动计划研究型医师创新转化能力培训项目(SHDC2022CRS053)

上海申康医院发展中心《促进市级医院临床技能与临床创新三年行动计划(2023-2025年)》CRU协同数据质量提升项目(SHDC2024CRX032)

上海市皮肤病医院引进人才科研基金(2021KYQD01)

出版年

2024
世界临床药物
上海医药工业研究院

世界临床药物

CSTPCD
影响因子:0.849
ISSN:1672-9188
参考文献量6
段落导航相关论文